Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation, Surgery.

University Hospital Eppendorf, Hamburg, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:City/State/Province:Hamburg
Treatments:Chemotherapy, Radiation, SurgeryHospital:University Hospital Eppendorf
Drugs:Journal:Link
Date:Apr 2003

Description:

Patients: This Phase III study involved 240 patients, half of whom received the BCNU (gliadel) wafer. Of the 120 patients who received the wafer, 101 had glioblastoma multiforme, 13 had anaplastic gliomas, and 6 had other types of cancer (primary brain or metastasis to brain).

Treatment: Carmustine (BCNU) wafers and radiation therapy.

Toxicity: Toxicities included: abnormal gait, amnesia, aphasia, ataxia, brain edema, confusion, convulsion, depression, dizziness, facial paralysis, grand mal convulsions, hemiplegia, incoordination, intracranial hypertension, neuropathy, and speech disorder. Toxicity grades were not used.

Results: Median survival for the BCNU (gliadel) wafer-treated glioblastoma multiforme patients was 13.5 months.

Support: This study was sponsored and funded by Guilford Pharmaceuticals. Guilford Pharmaceuticals markets gliadel wafers.

Correspondence: Manfred Westphal, MD




Back